Total Payments
$513.51
2024 Payments
$196.07
Companies
8
Transactions
24
Medicare Patients
2,041
Medicare Billing
$130,381
Payment Breakdown by Category
Food & Beverage$513.51 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $513.51 | 24 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $298.45 | 13 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $64.90 | 3 | $0 (2024) |
| ABBVIE INC. | $47.05 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $33.85 | 1 | $0 (2021) |
| Boston Scientific Corporation | $25.97 | 1 | $0 (2022) |
| PFIZER INC. | $15.77 | 1 | $0 (2023) |
| Genentech USA, Inc. | $14.04 | 2 | $0 (2021) |
| Lilly USA, LLC | $13.48 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $196.07 | 7 | AstraZeneca Pharmaceuticals LP ($131.17) |
| 2023 | $135.83 | 7 | AstraZeneca Pharmaceuticals LP ($73.01) |
| 2022 | $84.38 | 4 | AstraZeneca Pharmaceuticals LP ($58.41) |
| 2021 | $97.23 | 6 | AstraZeneca Pharmaceuticals LP ($35.86) |
All Payment Transactions
24 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Respiratory | ||||||
| 08/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Cardio-renal | ||||||
| 06/05/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Respiratory | ||||||
| 04/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Cardio-renal | ||||||
| 04/02/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: Respiratory | ||||||
| 02/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Cardio-renal | ||||||
| 01/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $84.97 | General |
| Category: Respiratory | ||||||
| 11/29/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2023 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/22/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.24 | General |
| 07/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/05/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: NEUROSCIENCE | ||||||
| 05/31/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: NEUROSCIENCE | ||||||
| 03/20/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/19/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/01/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/23/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/10/2022 | Boston Scientific Corporation | General - Pain Management (Device) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: General - Pain Management_NMD | ||||||
| 12/16/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $2.72 | General |
| Category: Virology & Specialty Care | ||||||
| 09/08/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/03/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $33.85 | General |
| Category: NEUROSCIENCE | ||||||
| 04/28/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/29/2021 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: Diabetes | ||||||
| 01/27/2021 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $11.32 | General |
| Category: Virology & Specialty Care | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 418 | 1,051 | $133,154 | $31,544 |
| 2022 | 10 | 384 | 870 | $87,791 | $22,194 |
| 2021 | 11 | 450 | 936 | $85,099 | $29,602 |
| 2020 | 14 | 789 | 1,468 | $127,472 | $47,040 |
Total Patients
2,041
Total Services
4,325
Medicare Billing
$130,381
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 130 | 321 | $103,992 | $22,583 | 21.7% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2023 | 28 | 31 | $8,730 | $4,333 | 49.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 55 | $12,658 | $3,087 | 24.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 65 | 108 | $4,036 | $804.52 | 19.9% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 15 | 17 | $578.00 | $275.40 | 47.6% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 12 | 22 | $1,386 | $257.78 | 18.6% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 57 | 276 | $1,364 | $93.35 | 6.8% |
| 81003 | Automated urinalysis test | Office | 2023 | 21 | 25 | $125.00 | $55.00 | 44.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 15 | 15 | $104.00 | $41.73 | 40.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 27 | 181 | $181.00 | $13.90 | 7.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 116 | 218 | $64,071 | $15,949 | 24.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 22 | 22 | $7,676 | $2,107 | 27.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 33 | $7,044 | $1,855 | 26.3% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 27 | 56 | $1,820 | $914.20 | 50.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 65 | 94 | $3,249 | $691.59 | 21.3% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 18 | 37 | $2,219 | $351.80 | 15.9% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2022 | 12 | 12 | $401.00 | $195.37 | 48.7% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 59 | 276 | $1,124 | $85.92 | 7.6% |
| 81003 | Automated urinalysis test | Office | 2022 | 16 | 17 | $82.00 | $35.49 | 43.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 20 | 105 | $105.00 | $8.61 | 8.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 151 | 261 | $57,076 | $19,379 | 34.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 46 | 46 | $12,494 | $4,976 | 39.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 20 | $2,768 | $1,369 | 49.5% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 16 | 16 | $3,193 | $1,343 | 42.1% |
| 71046 | X-ray of chest, 2 views | Office | 2021 | 31 | 69 | $3,542 | $807.49 | 22.8% |
About Michael Gross, CRNP
Michael Gross, CRNP is a Nurse Practitioner healthcare provider based in Rainbow City, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1518256007.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Gross, CRNP has received a total of $513.51 in payments from pharmaceutical and medical device companies, with $196.07 received in 2024. These payments were reported across 24 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($513.51).
As a Medicare-enrolled provider, Gross has provided services to 2,041 Medicare beneficiaries, totaling 4,325 services with total Medicare billing of $130,381. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Nurse Practitioner
- Location Rainbow City, AL
- Active Since 04/05/2011
- Last Updated 11/06/2015
- Taxonomy Code 363L00000X
- Entity Type Individual
- NPI Number 1518256007
Products in Payments
- FARXIGA (Drug) $149.04
- AIRSUPRA (Drug) $131.17
- Kerendia (Drug) $64.90
- VRAYLAR (Drug) $47.05
- TRINTELLIX (Drug) $33.85
- General - Pain Management (Device) $25.97
- PAXLOVID (Drug) $15.77
- Xofluza (Drug) $14.04
- TRULICITY (Drug) $13.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.